1. Ege Tıp Dergisi
  2. Archive
  3. Issue
Year 2021, Volume , Issue , Pages 32 - 35 2021-01-20

Rational drug use: Novel oral anticoagulants
Akılcı ilaç kullanımı: Yeni nesil oral antikoagülanlar

Nur AKAD SOYER [1]

Abstract

Novel oral anticoagulants have been developed as an alternative to the disadvantages of vitamin K antagonists. Nowadays, novel oral anticoagulants are indicated in stroke prevention in patients with nonvalvular atrial fibrillation, prevention of venous thromboembolism after hip or knee replacement surgery and treatment of venous thromboembolism. We review properties of novel oral anticoagulants, indications, recommendations for their laboratory monitoring, reversal agents, and periprocedural management of patients.
Yeni nesil oral antikoagülanlar, K vitamini antagonistlerinin dezavantajlarına alternatif olarak geliştirilmişlerdir. Günümüzde yeni nesil oral antikoagülanlar, non-valvuler atrial fibrilasyonda inmenin önlenmesinde, total kalça ve diz protezi sonrası derin ven trombozunun önlenmesinde ve tromboemboli tedavisinde kullanılmaktadır. Biz bu makalede yeni nesil oral antikoagülanların özelliklerini ve kullanım alanlarını, laboratuvar izlemini, antidotlarını ve girişimsel işlemlerde hastaların yönetimini gözden geçirdik.

References

  • Hirsh J, Fuster V, Ansell J, Halperin JL; American Heart Association, American College of Cardiology Foundation. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 2003; 107 (12): 1692-711.
  • Trikha R, Kowey PR. Practical considerations for the nonvitamin K antagonist oral anticoagulants. Cardiology 2017; 136 (2): 115-24.
  • Levy JH, Douketis J, Weitz JI. Reversal agents for non-vitamin K antagonist oral anticoagulants. Nat Rev Cardiol 2018; 15 (5): 273-81.
  • Reddy ST, Cossey TC, Savitz SI, Grotta JC. Non-vitamin K oral anticoagulants (NOACs) and their reversal. Curr Neurol Neurosci Rep 2017; 17: 67.
  • Barnes GD, Kurtz B. Direct oral anticoagulants: unique properties and practical approaches to management. Heart 2016; 102 (20): 1620-6.
  • Verdecchia P, Angeli F, Aita A, Bartolini C, Reboldi G. Why switch from warfarin to NOACs? Intern Emerg Med 2016; 11 (3): 289-93.
  • Abed HS, Kilborn MJ, Chen V, Sy RW. Reversal Agents in the Era of NOACs. J Atr Fibrillation 2017; 10 (4): 1634.
  • Milling TJ Jr, Ziebell CM. A review of reversal of oral anticoagulants, old and new, in major bleeding and the need for urgent surgery. Trends Cardiovasc Med 2019. pii: S1050-1738 (19) 30041-6.
  • Amin A. Choosing non-vitamin K antagonist oral anticoagulants: Practical considerations we need to know. Ochsner J 2016;16 (4): 531-41.
  • Gelosa P, Castiglioni L, Tenconi M, et al. Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs). Pharmacol Res 2018; 135: 60-79.
  • Arias Pou P, González A, Martínez LJP, Latorre AD, Alonso MS. Periprocedural management of patients receiving novel oral anticoagulants. Eur J Hosp Pharm 2018; 25 (6): 292-7.

Details

Primary Language tr
Subjects Health Care Sciences and Services
Journal Section Case Reports
Authors

Orcid: 0000-0002-7722-506X
Author: Nur AKAD SOYER
Institution: EGE TIP FAKÜLTESİ
Country: Turkey
Dates

Application Date : April 6, 2020
Acceptance Date : August 28, 2020
Publication Date : January 20, 2021

Cite

Bibtex @case report { etd864141, journal = {Ege Tıp Dergisi}, issn = {1016-9113}, eissn = {2147-6500}, address = {}, publisher = {Ege University}, year = {2021}, volume = {}, pages = {32 - 35}, doi = {10.19161/etd.864141}, title = {Akılcı ilaç kullanımı: Yeni nesil oral antikoagülanlar}, key = {cite}, author = {Akad Soyer, Nur} }
APA Akad Soyer, N . (2021). Akılcı ilaç kullanımı: Yeni nesil oral antikoagülanlar . Ege Tıp Dergisi , Volume: 60 Suppl: 1 (Rheumatology) , 32-35 . DOI: 10.19161/etd.864141
MLA Akad Soyer, N . "Akılcı ilaç kullanımı: Yeni nesil oral antikoagülanlar" . Ege Tıp Dergisi (2021 ): 32-35 <http://egetipdergisi.com.tr/en/pub/issue/59812/864141>
Chicago Akad Soyer, N . "Akılcı ilaç kullanımı: Yeni nesil oral antikoagülanlar". Ege Tıp Dergisi (2021 ): 32-35
RIS TY - JOUR T1 - Akılcı ilaç kullanımı: Yeni nesil oral antikoagülanlar AU - Nur Akad Soyer Y1 - 2021 PY - 2021 N1 - doi: 10.19161/etd.864141 DO - 10.19161/etd.864141 T2 - Ege Tıp Dergisi JF - Journal JO - JOR SP - 32 EP - 35 VL - IS - SN - 1016-9113-2147-6500 M3 - doi: 10.19161/etd.864141 UR - https://doi.org/10.19161/etd.864141 Y2 - 2020 ER -
EndNote %0 Ege Tıp Dergisi Akılcı ilaç kullanımı: Yeni nesil oral antikoagülanlar %A Nur Akad Soyer %T Akılcı ilaç kullanımı: Yeni nesil oral antikoagülanlar %D 2021 %J Ege Tıp Dergisi %P 1016-9113-2147-6500 %V %N %R doi: 10.19161/etd.864141 %U 10.19161/etd.864141
ISNAD Akad Soyer, Nur . "Akılcı ilaç kullanımı: Yeni nesil oral antikoagülanlar". Ege Tıp Dergisi / (January 2021): 32-35 . https://doi.org/10.19161/etd.864141
AMA Akad Soyer N . Akılcı ilaç kullanımı: Yeni nesil oral antikoagülanlar. ETD. 2021; 32-35.
Vancouver Akad Soyer N . Akılcı ilaç kullanımı: Yeni nesil oral antikoagülanlar. Ege Tıp Dergisi. 2021; 32-35.
IEEE N. Akad Soyer , "Akılcı ilaç kullanımı: Yeni nesil oral antikoagülanlar", Ege Tıp Dergisi, pp. 32-35, Jan. 2021, doi:10.19161/etd.864141
Authors of the Article
Nur AKAD SOYER [1]
Submit Article
Archive
Editorial Board
Contact
TR Dizin
TR Dizin

17243172461724517247   17240  17237         ehost_logo.gif